Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients?

Laura EvangelistaViviana Frantellizzi Orazio Schillaci Luca Filippi

Published in: Expert review of anticancer therapy (2023)

= 9 patients, totally) are now available. Radiolabeled-FAPI is a promising agent for the identification of pancreatic malignant lesions, but further prospective studies are still necessary.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes